A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

por Langley, Joanne M., Aggarwal, Naresh, Toma, Azhar, Halperin, Scott A., McNeil, Shelly A., Fissette, Laurence, Dewé, Walthere, Leyssen, Maarten, Toussaint, Jean-François, Dieussaert, Ilse
Publicado 2017

Hamster neogenin, a host-cell protein contained in a respiratory syncytial virus candidate vaccine, induces antibody responses in rabbits but not in clinical trial participants

por Steff, Ann-Muriel, Cadieux-Dion, Chanel, de Lannoy, Gaël, Prato, Maria Key, Czeszak, Xavier, André, Bruno, Ingels, Dominique C, Louckx, Marc, Dewé, Walthère, Picciolato, Marta, Maleux, Koen, Fissette, Laurence, Dieussaert, Ilse
Publicado 2020

Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans

por Burny, Wivine, Callegaro, Andrea, Bechtold, Viviane, Clement, Frédéric, Delhaye, Sophie, Fissette, Laurence, Janssens, Michel, Leroux-Roels, Geert, Marchant, Arnaud, van den Berg, Robert A., Garçon, Nathalie, van der Most, Robbert, Didierlaurent, Arnaud M.
Publicado 2017

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

por Beran, Jiři, Lickliter, Jason D, Schwarz, Tino F, Johnson, Casey, Chu, Laurence, Domachowske, Joseph B, Van Damme, Pierre, Withanage, Kanchanamala, Fissette, Laurence A, David, Marie-Pierre, Maleux, Koen, Schmidt, Alexander C, Picciolato, Marta, Dieussaert, Ilse
Publicado 2018

2488. The Impact of Reactogenicity After Administration of the Recombinant Zoster Vaccine Upon the Physical Functioning and Quality of Life of Older Adults

por Schmader, Kenneth E, Levin, Myron J, Grupping, Katrijn, Matthews, Sean, Butuk, David, Chen, Michael, Idrissi, Mohamed El, Fissette, Laurence A, Fogarty, Charles, Hartley, Paul, Klein, Nicola P, Nevarez, Max, Uusinarkaus, Kari, Oostvogels, Lidia, Curran, Desmond
Publicado 2018

The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial

por Schmader, Kenneth E, Levin, Myron J, Grupping, Katrijn, Matthews, Sean, Butuk, David, Chen, Michael, Idrissi, Mohamed El, Fissette, Laurence A, Fogarty, Charles, Hartley, Paul, Klein, Nicola P, Nevarez, Max, Uusinarkaus, Kari, Oostvogels, Lidia, Curran, Desmond
Publicado 2019

First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vec...

por Cicconi, Paola, Jones, Claire, Sarkar, Esha, Silva-Reyes, Laura, Klenerman, Paul, de Lara, Catherine, Hutchings, Claire, Moris, Philippe, Janssens, Michel, Fissette, Laurence A, Picciolato, Marta, Leach, Amanda, Gonzalez-Lopez, Antonio, Dieussaert, Ilse, Snape, Matthew D
Publicado 2020

119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated

por Tica, Jelena, Guiñazú, Javier Ruiz, Andrews, Charles P, Davis, Matthew G, Essink, Brandon, Fogarty, Charles, Kerwin, Edward, Leroux-Roels, Isabel, Steenackers, Katie, Vandermeulen, Corinne, David, Marie-Pierre, Dezutter, Nancy, Fissette, Laurence, Koch, Juliane, Mesaros, Narcisa
Publicado 2020

121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic

por Guiñazú, Javier Ruiz, Tica, Jelena, Andrews, Charles P, Davis, Matthew G, De Smedt, Philippe, Essink, Brandon, Fogarty, Charles, Kerwin, Edward, Leroux-Roels, Isabel, Vandermeulen, Corinne, David, Marie-Pierre, Dezutter, Nancy, De Schrevel, Nathalie, Fissette, Laurence, Mesaros, Narcisa
Publicado 2020

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)

por Ison, Michael G, Papi, Alberto, Langley, Joanne M, Lee, Dong-Gun, Leroux-Roels, Isabel, Martinon-Torres, Federico, Schwarz, Tino F, Van Zyl-Smit, Richard N, Dezutter, Nancy, De Schrevel, Nathalie, Fissette, Laurence, David, Marie-Pierre, Van Der Wielen, Marie, Kostanyan, Lusine, Hulstrøm, Veronica
Publicado 2022

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons

por Ison, Michael G, Papi, Alberto, Langley, Joanne M, Lee, Dong-Gun, Leroux-Roels, Isabel, Martinon-Torres, Federico, Schwarz, Tino F, Van Zyl-Smit, Richard N, Cuadripani, Susanna, Dezutter, Nancy, Gruselle, Olivier, Fissette, Laurence, David, Marie-Pierre, Olivier, Aurélie, Der Wielen, Marie Van, Descamps, Dominique
Publicado 2023

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

por Leroux-Roels, Isabel, Davis, Matthew G, Steenackers, Katie, Essink, Brandon, Vandermeulen, Corinne, Fogarty, Charles, Andrews, Charles P, Kerwin, Edward, David, Marie-Pierre, Fissette, Laurence, Vanden Abeele, Carline, Collete, Delphine, de Heusch, Magali, Salaun, Bruno, De Schrevel, Nathalie, Koch, Juliane, Verheust, Céline, Dezutter, Nancy, Struyf, Frank, Mesaros, Narcisa, Tica, Jelena, Hulstrøm, Veronica
Publicado 2022